HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Elana Drell Szyfer to assistant VP marketing-fragrance, sun and body, where her responsibilities include women's fragrance development. Prior to joining Lancome, Szyfer served as Avon's exec director-global personal care and fragrance and spent three years at Cosmair's Biotherm and the European Fragrances divisions. She reports to Lancome division VP Liz Falconer. Szyfer succeeds Renaud de Lesquen, who moves to international marketing for fragrance, sun and body

You may also be interested in...


Rouge Sensation Multi-Sensation Velvet LipColour with vitamins A, C and E offers "silkiest, sultriest matte possible," L'Oreal USA division says. Debuting in April in 12 hues such as Cognac, Ginger Root, Truffle and Mandarin, Velvet LipColour will retail for $18.50 and will be supported with ads featuring actress Uma Thurman. Firm's first American spokesmodel, Thurman signed with Lancome in June as the face for its Miracle fragrance, debuting stateside this month, as well as for skin care and color campaigns (1"The Rose Sheet" June 12, 2000, Marketing In Brief). Rouge Sensation Multi-Sensation LipColour line also expanded with five new shades ranging from lavish cremes to subtle pearls

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts